HKG:2228

5 stories mentioning HKG:2228Updated just now

Every FINWIRES story that references HKG:2228, newest first.

What's the latest news on HKG:2228?

XtalPi Unit, Stanford University Sign Drug Discovery Collaboration; Shares Rise 9%

XtalPi (HKG:2228) said its wholly owned subsidiary, LCC Technologies, has entered into a drug discovery collaboration with Stanford University, according to a Thursday filing with the Hong Kong bourse.The collaboration will combine Stanford's disease biology research with LCC Technologies' automated and AI-driven small-molecule discovery platform to develop potential new therapies.Shares of the firm were up nearly 9% in Friday morning trade.

HKG:2228

Asia29d ago

XtalPi Swings into Losses in H1; Revenue Slides

XtalPi (HKG:2228) reported a loss attributable to equity holders of the company of 251.9 million yuan for the first half compared with a profit of 82.8 million yuan a year earlier.The biotech company's loss per share stood at 0.06 yuan, compared with earnings per share of 0.02 yuan in the year-ago period, according to a Wednesday filing with the Hong Kong Exchange.Revenue decreased to 393.6 million yuan for the six months ended June 30 from 517.1 million yuan.

HKG:2228

Asia52d ago

XtalPi Expects to Swing to H1 Loss

XtalPi (HKG:2228) expects to report a net loss attributable to shareholders of 215 million yuan to 275 million yuan for the first half of 2026, compared with a net profit of 82.8 million yuan a year earlier.The company expects revenue of 380 million yuan to 400 million yuan, down from 517.1 million yuan a year earlier, primarily due to the absence of a $51 million upfront payment from a major pipeline licensing project recognized in the prior-year period, according to a Hong Kong bourse filing.The pharma research firm also cited a more than 50% increase in research and development spending driven by continued investment in autonomous laboratories, agentic systems and drug development programs.The company is expected to report interim results by the end of August.

HKG:2228

Asia100d ago

XtalPi Signs Drug Development Agreement with Potential Value of Over $400 Million

XtalPi (HKG:2228) entered into a partnership with an international biopharmaceutical company to develop an oral small-molecule therapy targeting a G protein-coupled receptor, according to a Tuesday Hong Kong bourse filing.The agreement carries a potential value of more than $400 million, including an upfront payment, research funding, development and commercial milestone payments, and future royalties.Under the deal, the partner will fully fund XtalPi's early-stage research and development work.Shares of the firm were down over 2% in late morning trade on Wednesday.

HKG:2228

Asia113d ago

XtalPi Receives Further $19 Million Under Drug Discovery Agreement With DoveTree

XtalPi Holdings (HKG:2228) said it received a further $19 million payment from DoveTree Medicines under an AI-driven drug discovery services agreement, according to a Wednesday filing with the Hong Kong bourse.The bio-tech platform's shares gained over 3% recent trade.The firm had previously agreed to use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas that would then be licensed to DoveTree.XtalPi received an upfront payment of $51 million at the time and is eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales.

HKG:2228

Track with the FINWIRES app suite

FolioX

Track HKG:2228 in your portfolio

WheelAI

Analyze HKG:2228 options with the wheel strategy

StockInsider

See market sentiment on HKG:2228